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Introduction  
Rabies is highly fatal viral encephalitis caused by a number of 
different strains of highly neurotrophic viruses 1 belonging to a single 
serotype in the genus lyssavirus, family rhabdoviridae. Immunization, both 
active and passive, remains the mainstay of prophylaxis against rabies.  
Cell culture based rabies vaccines are slowly replacing the nervous tissue 
rabies vaccine in prophylaxis against rabies 2. However isolated reports of 
development of rabies, despite immunization with cell culture derived 
rabies vaccine, from developing countries including India, are questioning 
the authenticity of prophylactic measures and the vaccines used for 
prophylaxis 3, 4, 5, 6,7. One of the proposed causes for cell culture derived 
rabies vaccine failure is being the inadequate vaccine potency due to 
exposure to non-ideal temperatures during storage and transportation 3,7. 
In India, similar to other developing countries, due to frequent power cut, 
lack of storage facilities and trained staff, maintenance of cold chain for 
vaccines is often inadequate. Therefore estimation of the potency of cell 
culture rabies vaccines from the community has been suggested 3. 
 
This prompted us to study the rabies vaccine storage practices in 
pharmacies based in three districts spread across three south Indian 
states and to estimate the potency of cell culture rabies vaccines obtained 
from the community.   
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Aim and Objectives 
Aim 
 
To determine whether reduced potency due to inadequate cold chain 
maintenance is the cause for cell culture derived rabies vaccine failure. 
 
Objectives 
 
1. To study the rabies vaccine storage practices in the community. 
2. To estimate the glycoprotein content in cell culture derived rabies  
    vaccines as an indirect measure of vaccine potency.  
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REVIEW OF LITERATURE 
Cold Chain 
 
Vaccines are biological products and are susceptible to fluctuations in 
temperature. Vaccines must be stored properly from the time they are 
manufactured until the time they are administered. Excessive heat or cold 
exposure damages vaccine, resulting in loss of potency 8. Once potency is 
lost, it can never be restored. Furthermore, each time the vaccine is exposed 
to heat or cold, the loss of potency increases and eventually, if the cold chain 
is not correctly maintained, all potency will be lost, and the vaccine becomes 
useless. In some cases, heat exposure leading to loss of vaccine potency 
may also cause the vaccine to become more reactogenic 9. The system used 
to keep and distribute vaccines in good condition is called the “cold chain.” 9 
This consists of a series of storage and transport links, all of which are 
designed to keep the vaccine at the correct temperature until it reaches the 
consumer. The cold chain has three main components: transport and storage 
equipment, trained personnel, and efficient management procedures. All 
three elements must combine to ensure safe vaccine transport and storage. 
 
The cold chain begins with the refrigerator or freezer at the vaccine 
manufacturing plant, extends through the transfer of vaccine to the distributor 
and then to the provider’s office, and ends with the administration of the 
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vaccine to the recipient 9. Proper storage temperatures must be maintained at 
every link in the chain. 
Fig 1. A typical cold chain system for vaccines 
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Requirements during vaccine transportation  
Manufacturers and central pharmacies ship their vaccines in 
insulated containers, with documented ability to maintain the appropriate 
temperature for the anticipated maximum length of time required for the 
transportation, carrying appropriate number of ice packs. Containers 
should be fitted with both heat and cold monitors 10. In case of long 
distance shipments they should use electronic monitors to detect possible 
problems and their location. Shipping boxes for most vaccines should be 
clearly labeled as containing perishable goods that have to be stored 
between 2 and 8o C and must not be frozen. To avoid freezing, vaccines 
should not be placed directly on the ice pack 11. If evidence of freezing is 
present when vaccines sensitive to freezing are received (e.g., results of 
temperature measurements), the vaccine must not be used 11.  
Vaccine storage requirements  
Vaccines should be stored in the refrigerator as soon as they are 
received. Vaccines should never be removed from the refrigerator except 
for the following reasons: withdrawing a dose(s); shipping to clients; or 
transporting to immunization clinics. The refrigerator door should not be 
opened too frequently. The World Health Organization recommends that 
the door should not be opened more than four times a day 12. 
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Any refrigerator or freezer used for vaccine storage must maintain 
the required temperature range year-round, be large enough to hold the 
year's largest inventory, and be dedicated to storage of biologics i.e., food 
or beverages should not be stored in vaccine storage units 13. If there is an 
accumulation of more than 1 cm ice in the freezer compartment of a 
refrigerator, defrosting is required. Vaccines should be transferred to a 
vaccine carrier box or another refrigerator while this is being done 14. The 
temperature should be monitored during this emergency period. 
Refrigerator plugs should be protected in an area where they cannot be 
knocked out accidentally. Procedures in the event of vaccine refrigerator 
failure should be posted on or near all such refrigerators. If a power 
outage occurs, all vaccines should be transferred into a thermal cold box 
or a container with ice packs, until the vaccines can be transferred to 
another refrigerator. If a short power outage is anticipated (less than 1 
hour), the storage unit should not be opened. If a longer power outage is 
anticipated, then plans for transfer are warranted. Regular maintenance of 
refrigerators (cleaning coils, replacing door seals, etc.) should be 
performed and records kept. 
Vaccines should never be stored on refrigerator door shelves 
because temperatures are warmer there than on the shelves of the 
refrigerator13. Space should be left between the products in the refrigerator 
to allow air to circulate. For freeze-dried products, for which diluent is 
provided in separate packages, the diluent should be stored at room 
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temperature to conserve refrigerator space, unless the vaccine direction 
insert specifies that the diluents must be refrigerated. All adsorbed 
vaccines should be kept away from the freezing element and away from 
direct contact with ice. Water bottles should be kept at the bottom, the top, 
and in the door spaces of the vaccine refrigerator, and ice packs should 
be kept in the freezer compartment to maintain a more constant 
temperature if there is a power failure. Educational material on the cold 
chain should be available in all centers storing vaccines.  
 
All staff handling vaccines should have training about the 
importance of good vaccine storage, correct storage temperatures for the 
various vaccines and transportation techniques. They should know how to 
read and interpret maximum-minimum thermometers. One person should 
be identified as responsible for vaccine management. Another individual 
should also be trained for when the first person is absent. 
 
Vaccine refrigerator should be placed in a room with a lockable 
door to prevent unauthorized handling or refrigerator entry after office 
hours. If this is not possible, a low traffic area should be considered. 
Refrigerators with lockable doors should be secured after office hours. If a 
product(s) is (are) known to have been exposed to temperatures outside 
of the recommended range, the exposed product(s) should be put in a box 
marked "DO NOT USE" and placed in a functioning refrigerator. The types 
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of products exposed should be recorded, as well as the duration and 
temperature of exposure, and advice on whether these products may be 
used or returned should be sought immediately. 
Temperature monitoring  
Proper temperature monitoring is key to proper cold chain 
management 15. All vaccine storage refrigerators should have a maximum 
minimum thermometer or, if large quantities of vaccines stored, a 
continuous temperature recording device. Thermometers should be 
placed in a central location in the storage unit, adjacent to the vaccine. 
Different types of thermometers can be used, like standard fluid-filled, min-
max, and continuous chart recorder thermometers 15. Comparison of 
different thermometers used for monitoring vaccine storage compartment 
temperatures is given in Table 1. All monitoring devices should be certified 
or calibrated routinely. All refrigerators containing large quantities of 
vaccine (e. g central vaccine distributing areas) should also be connected 
to a temperature alarm monitoring system. Two daily temperature 
readings for the vaccine refrigerator should be taken and recorded — one 
in the morning when arriving and one at the end of the day — to ensure 
temperatures remain between 2 and 8oC15. A chart-recording thermometer 
should also be checked for temperature fluctuations, which may occur 
between readings. In addition, temperature indicators (e.g., Freeze 
Watch™ [3M, St. Paul, Minnesota] or Cold Mark™ [Cold Ice, Inc., Oakland, 
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California] ) can be considered as a backup monitoring system. However, 
such indicators should not be used as a substitute for twice daily 
temperature readings and documentation.  
Table 1: Comparison of thermometers used to monitor vaccine temperatures 
Thermometer type                  Advantages        Disadvantages 
Standard fluid filled  Inexpensive & simple Less accurate (+ / - 10 C) 
No information on duration 
of out of specification 
exposure 
Cannot be recalibrated 
Min – Max   Inexpensive   Less accurate (+ / - 10 C) 
No information on duration 
of out of specification 
exposure 
Cannot be recalibrated 
Continuous recorder Most accurate            Most expensive    
Continuous 24-hr   Requires training and 
 readings of temperature maintenance   
 range and duration  
Can be recalibrated at      
 regular intervals 
 
The majority of commonly recommended vaccines require storage 
temperatures of 35 to 46°F (2 to 8°C) and must not be exposed to freezing 
temperatures.  
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Table 2: Vaccines and testing solution that must be stored between 2 and 8°C 
  
 
1. Diphtheria and tetanus toxoids 
2. Diphtheria and tetanus toxoids and pertusis vaccine (acellular) 
3. Diphtheria and tetanus toxoids, adsorbed pertusis vaccine (acellular) and 
inactivated polio vaccine 
4. Diphtheria and tetanus toxoids, adsorbed pertusis vaccine (acellular) , 
inactivated polio vaccine and haemophilus influenzae type b (Hib) 
conjugate vaccine 
5. Hepatitis A vaccine 
6. Hepatitis B vaccine 
7. Hib conjugate vaccine 
8. Inactivated polio vaccine 
9. Influenza vaccine 
10. Mumps, measles , rubella vaccine * 
11. Meningococcal C vaccine 
12. Pneumococcal 7- valent conjugate vaccine  
13. Pneumococcal polysaccharide 23- valent vaccine  
14. Rabies vaccine 
15. Rabies immunoglobulin 
16. Tuberculosis testing solution 
17. Varicella vaccine * 
 
 
* The diluents of these vaccines do not have to be stored in the refrigerator 
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Inadequacy in vaccine cold chain maintenance  
Good practices to maintain proper vaccine storage and handling 
can ensure that the full benefit of immunization is realized. Provision of 
adequate equipment and training for staff in maintaining the "cold chain" 
and the use and care of equipment are important components of a 
successful immunization programme 16. In recent years, instances of 
improper vaccine storage have been reported. An estimated 17 to 37% of 
providers expose vaccines to improper storage temperatures 17, 18. Poor 
knowledge about storage and handling of vaccines by vaccine handlers, 
refrigerator temperatures outside the recommended range 19, using old 
and defective refrigerators for storing vaccines 20, frequent power cuts and 
lack of alternate power facilities 21 seem to be responsible for cold chain 
breakdown in the community based pharmacies. In India also, similar 
scenario exists as reports suggest that poor knowledge and improper 
practice of vaccine storage is common among the vaccine handlers 22,23 
and defective power supply is affecting the cold chain 24 . 
 
Rabies  
Rabies is a zoonosis of certain mammalian species, endemic in all 
continents. Only a few European countries, some islands and peninsulas 
and Antarctica, are free of rabies, although imported infection is a 
universal risk. The urban enzootic in domestic dogs is of most importance 
to man, and is the cause of more than 95% of human rabies cases. The 
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incidence of rabies is unknown due to the gross under-reporting of an 
untreatable disease whose victims often choose to die at home, to avoid 
the expense of medical care. The highest recognized human mortality is in 
Asia. In India alone 30000 deaths (3 /105 population) were reported to 
WHO in 1998 25. Human rabies continues to be endemic in India except 
for the islands of Andaman, Nicobar, and Lakshadweep. According to a 
recent report the annual incidence of human rabies in India is estimated to 
be 20565 or about 2 per 100000 populations 26. The majority of the victims 
in India are male, adult, from rural areas, and unvaccinated 26.  
 
The lyssaviruses 
Rabies is caused by the bullet-shaped RNA virus from 
Rhabdoviridae family. The ribonucleoprotein complex core of the virus is 
covered by a glycoprotein coat bearing projecting spikes 27. Rabies is the 
first of seven genotypes. The other six genotypes are rabies-related 
viruses 28, five of which can cause fatal infection 29. Two genotypes (5 and 
6) are European bat lyssaviruses found in insectivorous bats across 
Europe. Australian bat lyssavirus (genotype 7) was discovered in flying 
foxes (fruit bats, genus Pteropus), in 1996 30. Two further genotypes (3 
and 4), Mokola virus found in shrews and cats, and Duvenhage virus 
found in bats, are very occasionally seen in Africa 27,29. The Lyssavirus 
genus has recently been divided into two phylogroups based on 
serological and genetic analyses 28. Phylogroup I comprise all these 
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viruses except Mokola virus, which is in phylogroup II with Lagos Bat virus, 
which has not been found in humans. All phylogroup I genotypes have 
caused fatal rabies-like encephalitis in man, whereas Mokola virus has 
probably only caused three known human infections, one of which was a 
fatal encephalitis without any typical features of rabies 29. Experimentally, 
phylogroup II viruses are less pathogenic, and there is little if any cross-
neutralization with the phylogroup I lyssaviruses. This is of practical 
relevance for post-exposure treatment. 
Transmission 
 
Rabies is an infection initially of wild and then domestic animals, 
which is spread to humans by bites, contact with mucosal membranes, 
and (to a much lesser extent) aerosol inhalation in bat caves. Most 
infections (90%) are transmitted via domestic animals (cats and dogs), 
mainly due to their close association with humans 31. Infection can 
occasionally occur via scratches infected with saliva, though the infection 
rate is 50 times lower 32. The main animals responsible for bites are dogs 
(96.2%), most of which are stray. The most common bite sites are the 
extremities 26. Human to human transmission has not been recorded, with 
the exception of six iatrogenic cases resulting from corneal graft implants 33 
and four cases of organ transplant 34. Airborne transmission is thought to 
have occurred in two men who inhaled virus aerosols generated in caves 
inhabited by rabid bats, and in a laboratory worker who became infected 
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while rabid sheep brains were being ground for vaccine production 35 .The 
virus may be shed in breast milk, and there has been at least one 
suspected case of transmission from a mother to her breastfed infant 36. 
Transplacental infection occurs in animals 37 but has not been reported in 
humans. A number of women with rabies encephalitis are known to have 
delivered healthy babies.  
Pathogenesis 
After a bite, the virus replicates in muscle cells close to the site of 
the bite and then ascends to the central nervous system via the peripheral 
nerves 38. On reaching the central nervous system, there is massive viral 
replication on membranes within neurons 39. Later through retrograde 
axonal transport from the brain, via somatic and autonomic efferent nerves, 
virus is deposited in many tissues 39 including: skeletal and cardiac muscle, 
adrenal medulla, kidney, taste buds, respiratory tract, cornea, and nerve 
twiglets in the hair follicles. At this stage, productive viral replication occurs, 
with budding from outer cell membranes in the salivary, lacrimal and other 
glands, which permits further transmission of rabies by bites to other 
mammals.   
 
The incubation period from bite to disease varies widely, but is 
usually between 30 and 90 days. Antigenic analysis has confirmed 
incubation periods of up to 7 years 40, although this is exceptional. Bites on 
the head and neck have a shorter incubation period (sometimes even as 
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short as 15 days) compared with those on the trunk and lower extremities, 
due to the decreased length and greater number of neurons. A recent 
report from India also suggests a disease incubation period ranging from 
two weeks to six months 26. 
Following infection, the brain, spinal cord, and peripheral nerves 
show ganglion cell degeneration, perineural and perivascular mononuclear 
cell infiltration, and neuronophagia 41. Inflammation is most marked in the 
midbrain and medulla in furious rabies 42 and in the spinal cord in paralytic 
rabies 43. Vascular lesions such as thrombosis and hemorrhage are also 
described, mainly in the brainstem, hypothalamus, and limbic system. 
Outside the nervous system, there is focal degeneration of the salivary and 
lachrymal glands, pancreas, and adrenal medullae  44. 
Immunology 
Rabies virus evades recognition by the immune system until the 
late stage of the disease. At the site of inoculation, some virus may be 
briefly exposed, but once within neurons, virions and their antigens are 
hidden from immune surveillance. When virus is eventually secreted, 
rabies antigens are expressed on cell surfaces but the virus is then widely 
distributed throughout the body and an immune response is too late to 
combat the overwhelming infection. Neutralizing antibody usually appears 
during the second week of illness in unvaccinated patients, and remains at 
low levels until death a few days later 45. Evidence of cell mediated 
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immunity, by lymphocyte transformation tests, was found in six of nine 
furious encephalitis patients, but not in seven with paralytic disease 46, 
who had few B cells. Both groups had reduced NK cell levels 47. Studies of 
encephalitis in rodents show that survival or delayed mortality are 
associated with the early appearance of IFN-ı in the brain and neutralizing 
antibody 48,49,50 and also inflammation and up- regulation of MHC class II 
mRNA expression in CNS cells 51.  
 
Rabies virus glycoprotein  
The rabies virus glycoprotein is a major contributor to the 
pathogenicity of the virus 52. Rabies virus glycoprotein consists of three 
domains: cytoplasmic, transmembrane and ectodomain. It occurs in a 
complete, membrane-bound form within infected cells, but it is released 
from them in a deleted, secreted form lacking the transmembrane domain 
53.  Several rabies virus glycoprotein associated pathogenic mechanisms 
have been identified: (i) rabies virus glycoprotein must interact effectively 
with cell surface molecules that can mediate rapid virus uptake 54. (ii) 
rabies virus glycoprotein is essential for efficient virus budding 55 (iii) 
expression levels of rabies virus glycoprotein must be controlled to prevent 
functional impairment of the infected neuron 56 and (iv) the transmembrane 
domain of rabies virus glycoprotein is important for generating protection 
against rabies and should be present in rabies virus DNA vaccines . The 
cell culture rabies vaccine potency depends on the amount of 
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immunogenic rabies viral glycoprotein antigen in the vaccine preparation57. 
Estimation of the rabies viral glycoprotein antigen, using a specific 
monoclonal antibody based ELISA 57 and single-radial - immunodiffusion 
(SRD) are being promoted as alternatives to the conventional in vivo tests 
for immunogenicity  58.  
 
CLINICAL FEATURES 
Prodromal symptoms 
Itching or paraesthesiae at the site of the healed bite wound are the 
only specific prodromal symptoms, occurring in about 40% of patients. 
Non-specific features include: fever, headache, myalgia, fatigue, sore 
throat, gastrointestinal symptoms, irritability, anxiety and insomnia. 
Psychiatric disease may be suspected. The disease progresses to either 
furious or paralytic rabies encephalitis, usually within a week 59. 
 
Furious rabies 
This well-known form is recognized with characteristic hydrophobic 
spasms and sometimes with generalized extension, convulsions and 
opisthotonos posture 60. Respiratory or cardiac arrest following a 
hydrophobic spasm is fatal in one-third of cases. Excitation, aggression, 
anxiety or hallucinations occur between calm, lucid intervals, when no 
neurological abnormality may be detectable. Other features include 
cardiac arrhythmias, myocarditis, labile blood pressure and temperature, 
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respiratory disturbances (e.g. Cheyne–Stokes respiration, cluster 
breathing), meningismus, III, VII and IX cranial nerve palsies, abnormal 
pupillary responses, muscle fasciculation, autonomic stimulation with 
lacrimation and salivation and rarely increased libido, priapism and 
spontaneous orgasms 60. Coma eventually ensues, with flaccid paralysis, 
and the illness rarely lasts more than a week without intensive care.  
 
Paralytic rabies 
Less common than furious rabies, paralytic or ‘dumb’ rabies may be 
missed unless there is a high level of suspicion. Paralytic disease is 
characteristic of vampire bat transmitted rabies and is more common 
following infections by attenuated viruses, and perhaps after post-
exposure vaccination 29. Prodromal symptoms are followed by 
paraesthesiae or hypotonic weakness, commonly starting near the site of 
the bite and spreading cranially. Fasciculation, myoedema or piloerection 
may be seen. The ascending paralysis results in constipation, urinary 
retention, respiratory failure and inability to swallow. Flaccid paralysis, 
especially of proximal muscles, is associated with loss of tendon and 
plantar reflexes, but sensation is often normal. Hydrophobic spasms may 
occur in the terminal phase and death ensues after 1 to 3 weeks 60. 
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Management 
In case of suspected animal bites, aim is to prevent the 
development of rabies. The most important steps are thorough cleaning of 
the wound and use of post-exposure prophylaxis, which together reduce 
the risk from a known rabid animal bite from 37 to 60% to nearly zero 61. In 
case of large gaping wounds suturing should be postponed. Tetanus 
prophylaxis should be given. A prophylactic antimicrobial therapy should 
be given for serious bites or those on the hands.  Once rabies symptoms 
have developed, treatment itself is mainly supportive, as the prognosis is 
poor. Patients must be heavily sedated in order to control their pain and 
terror. Ketamine has been suggested as an appropriate agent for this 
purpose 62. The mainstay of treatment is intensive care support, including 
paralysis, sedation, and ventilation. Patients given intensive care develop 
complications such as cardiac arrhythmias, cardiac and respiratory failure, 
raised intracranial pressure, convulsions, fluid and electrolyte disturbances 
including diabetes insipidus and inappropriate secretion of antidiuretic 
hormone, and hyperpyrexia. Antiviral agents including intrathecal tribavirin 
(ribavirin) and interferon, rabies immunoglobulin, corticosteroids and other 
immunosuppressive drugs have proved useless in treating rabies 63. 
 
Survival after rabies encephalitis  
Although humans with paralytic rabies can survive for several 
weeks, especially with intensive care 64 the illness progresses persistently. 
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Till now only six patients have been documented as surviving rabies 
infection 65. Survivors are usually left with neurological deficits 62.  
 
RABIES PROPHYLAXIS 
Active immunization - Rabies vaccines 
Rabies vaccine preparations  are fluid or dried preparations of 
rabies ”fixed” virus grown in the neural tissues of rabbits, sheep, goats, 
mice or rats or in embryonated duck eggs, or in cell cultures, and 
inactivated by treatment with phenol or β-propiolactone . Five groups of 
rabies fixed strains are used to produce human rabies vaccines: Pasteur, 
Beijing, Flury, Fuenzalida and Street-Alabama-Dufferin (SAD) strains. The 
Pasteur-derived strains, Pasteur virus (PV) and Pitman-Moore (PM) 
strains), are  most widely used for the production of traditional vaccines of 
the Semple or Suckling Mouse Brain (SMB) types, but also for the 
production of modern cell culture vaccines. The different rabies vaccines 
are classified according to the cell system used to cultivate the virus. 
Animal systems are still employed to produce the old traditional vaccines - 
Semple and SMB - which continue to be produced in several countries. 
Primary cell systems, particularly Hamster kidney and Chick embryo cells, 
are also used.  Cell lines are presently the latest approach for vaccine 
production.  Following Pasteur’s initial development of rabies vaccine a 
variety of vaccines have been developed.  
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There are three types of rabies vaccines 
1. Nervous tissue vaccines (NTV) –  
 a. derived from adult animal nervous tissue (e.g. sheep) 
 b. derived from suckling mouse brain 
2. Duck embryo vaccine (DEV)   
3. Cell-culture vaccines -   
 a. Human diploid cell (HDC) vaccines 
 b. “second generation” tissue culture (animal cell) vaccines 
 
Three types of cell culture vaccines, one duck embryo vaccine and 
a nervous tissue vaccine are presently available in India 66.  
 
Nervous tissue vaccines  
A phenolized nerve-tissue vaccine was originally developed in India 
in 1911 by Sir David Semple at the central research institute, Kasauli , 
Himachal Pradesh.This is made from PV-11 strain of Pasteur fixed rabies 
virus infected sheep (Semple vaccine), goat, or mouse brains and is used 
in many parts of the world including Asia, Africa, and South America 67. It 
has a low potency per dose, and a complete treatment involves up to 23 
painful injections. NTVs are crude preparations capable of causing 
postvaccinal encephalitis with substantial frequency (0.05%).   
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The suckling-mouse brain (SMB) vaccine was developed at the 
Bacteriological Institute of Chile in 1954. This vaccine was originally used 
in dogs; use in humans was begun experimentally in 1960. Suckling 
mouse brain vaccine (SMB vaccine) is an improvement over adult animal 
NTVs as they have been prepared from the brains of suckling mice (less 
than 9 days old) which lack or contain less amount of myelin in their 
nervous tissue. Three strains of fixed rabies virus are used for the 
preparation of this vaccine: 2 strains isolated in Chile (strains 51 and 91, 
of dog and human origin respectively) and the challenge virus standard 
(CVS) strain. SMB vaccine is given in 10 daily doses plus booster doses 
10 and 20 days after the end of the primary series. These are extensively 
used in most of the Caribbean and all countries of Latin America. Its 
immunogenic potency is determined by the National Institutes of Health 
(NIH) test. 
 
Purified duck embryo vaccine (PDEV) 
PDEV has been developed in an attempt to eliminate 
neuroparalytic factors contained in the nervous tissue vaccines. The 
rabies virus is grown in embryonated duck eggs. Incidence of 
neuroparalytic reactions are less, however anaphylactic reactions are 
frequent. The antigenecity is low so that many (16 to 25) doses have to be 
given to obtain a satisfactory post exposure antibody response. It is 
available as “Vaxirab” (Zydus Recon) in India. 
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Purified chick embryo cell vaccine (PCECV) 
This vaccine is prepared from the fixed rabies virus strain Flury LEP 
grown in chicken fibroblasts. It is inactivated with β-propiolactone and 
further purified by zonal centrifugation. The vaccine potency is determined 
by the NIH test and the modified antibody-binding tests 68. The vaccine 
may be used up to 48 months from the date of release. It should be kept 
between 2 and 8°C 3. Rabipur ® is a highly purified, potent and efficacious 
PCECV rabies vaccine. It is the most widely used modern cell-culture 
rabies vaccine . In India also PCECV  is marketed as “Rabipur” (Aventis 
Pastuer). 
 
Purified vero cell vaccine (PVCV) 
The Vero cell line was established in 1962, starting from a primary 
culture of vervet monkey (Cercopithecus aethiops) kidney cells. The 
heteroploid VERO cell line was introduced in 1982 to the production of 
inactivated rabies vaccine; it has all the advantages of the Human Diploid 
Cell system. The Pitman-Moore (PM) strain of fixed rabies virus is used, 
after adaptation to growth in WI-38 cells. The virus suspension is 
inactivated using β-propiolactone. The vaccine may be used up to 36 
months from the date of release. It should be kept between 2 and 8°C 
after release 3. In India two brands of PVRV, “verorab” (Ranbaxy) and 
“Abhyarab” (Indian Immunologicals) are available. 
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Rabies vaccine, adsorbed (RVA) 
This vaccine is made in a diploid cell line derived from fetal rhesus 
monkey lung cells. The vaccine virus is inactivated with   β-propiolactone 
and concentrated by adsorption to aluminium phosphate. Currently it is not 
available in India. 
 
Human diploid cell vaccine (HDCV) 
The use of the human diploid cell system permitted the 
development of the HDCV, one of the most widely distributed cell culture 
rabies vaccine, and today considered as the reference vaccine. An 
inactivated rabies vaccine for human use was first prepared in cell culture 
in 1964. In 1966 it was shown that the human diploid cell (HDC) strain WI-
38 was a suitable substrate for the propagation of the Pitman -Moore (PM) 
stain of fixed rabies virus. The vaccine was first licensed for use in France 
in 1974 and commercial production started in 1978. The virus is now 
cultivated in MRC-5 human diploid cells, which are propagated and 
controlled according to the recommendations published by WHO and the 
regulations of national authorities. The vaccine virus is inactivated with β-
propiolactone and concentrated by ultrafiltration. No serious anaphylactic 
or encephalitic reactions have been reported. The potency of each lot of 
vaccine is determined by the NIH-Test 68. In India HDCV “Rabivax” is 
manufactured by the Serum Instute of India. 
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Rabies vaccine potency testing 
NIH test 
The potency of the rabies vaccine is established by the NIH test 
68. Groups of at least ten mice, aged 3 to 4 weeks, are inoculated with 
single, decreasing doses of vaccine in accordance with the European 
Pharmacopoeia 69, or with two doses, 1-week apart, according to the NIH 
test 70. A sufficient number of dilutions of vaccine are compared to 
estimate the dilution at which 50% of the mice are protected against 
intracerebral challenge with fixed-strain rabies virus. Many criticisms have 
been made regarding the NIH test in particular the high variability of the 
results, the fact that the test does not reproduce natural conditions of 
rabies vaccine use and that the choice of challenge strain affects NIH 
values 57. NIH test also induces substantial distress and suffering in 
laboratory mice. Since it involves use of virulent rabies virus it raises 
safety concerns and requires stringent biosafety measures. 
 
Immunocapture methods  
The vaccine potency depends on the amount of immunogenic 
rabies viral glycoprotein antigen in the vaccine preparation 57. The 
immunocapture methods based on the use of a neutralizing monoclonal 
anti-glycoprotein antibody seems to be convenient tools for the 
determination of the in vitro potency of rabies vaccine 71. The glycoprotein 
content of rabies vaccines containing the Pitman-Moore strain of rabies 
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virus measured by the single radial immunodiffusion assay has been 
shown to be correlating well with vaccine potency 72. An ELISA test using 
a specific monoclonal antibody to quantify the immunogenic rabies viral 
glycoprotein antigen in the inactivated rabies viral antigen preparation also 
indicated a good correlation with the NIH mouse potency assay 57. These 
two in vitro tests, i.e. single radial immunodiffusion test and ELISA, have 
been recommended by the WHO, for the partial replacement of in vivo 
potency test  73.  
 
Adverse effects of tissue culture vaccines 
Mild erythema, pain, headache, malaise, fever occur and very 
rarely neurological illness has been reported. There is very wide variation 
in the incidence of side-effects. A systemic allergic reaction has been 
observed in 6% of those vaccinated in the USA, 3 to 13 days following late 
booster injections of HDCV 74. The urticarial rash, angioedema and 
arthralgia respond to symptomatic therapy. It is possibly caused by an IgE 
mediated reaction to beta – propiolactone modified vaccine components  75.  
 
Pre-exposure vaccine regimens 
Pre-exposure prophylaxis regimen is given in Table 3. An 
economical intra dermal (i.d.) post-exposure treatment has been used for 
15 years in Asia 76. A booster dose by either route one year later 
enhances and prolongs the immune response, which lasts more than 10 
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years in 96% of people (intra muscular vaccine was used in this study ) 77. 
The level of antibody may be lower following i.d. vaccine, but the quality of 
the secondary immune response to a booster dose is similar for i.d and 
intra muscular (i.m.) injections.  A booster dose or an antibody test should 
be performed six monthly for rabies laboratory staff and all those at 
continued high risk of infection. For other people, if the antirabies antibody 
titre is < 0.5 IU, booster doses should be given every three years, and if > 
0.5 IU, boosters can be given every 10 years 78. If no serology is available, 
or affordable, boost every 5 to 10 years. Measurement of neutralizing 
antibody levels after treatment is necessary only if immunosuppresion is 
suspected, or to determine whether a repeated booster dose is needed. 
Chloroquine antimalarial chemoprophylaxis may inhibit the induction of 
rabies antibody after i.d. vaccination 79, so the larger dose must be given 
i.m. 
 
Post-exposure prophylaxis 
Regimen for post exposure prophylaxis is given in Table 5. 
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Table 3. Pre-exposure prophylaxis regimen   
 
Risk category 
 
 
Nature of risk 
 
 
Typical populations 
 
 
Pre-exposure 
recommendations 
 
Continuous 
 
Virus present 
continuously, often in 
high concentrations. 
Aerosol, mucous 
membrane, bite or 
non-bite exposure. 
Specific exposures 
may go unrecognized. 
 
Rabies research lab 
worker 1, rabies biologics 
production workers. 
 
Primary course. Serologic 
testing every 6 months; 
booster vaccination when 
antibody level falls below 
acceptable level 2 
 
 
Frequent 
 
Exposure usually 
episodic, with source 
recognized, but 
exposure may also be 
unrecognized. Aerosol, 
mucus membrane, 
bite, or non-bite 
exposure. 
 
Rabies diagnostic lab 
workers 1, spelunkers, 
veterinarians and staff, 
and animal-control and 
wildlife workers in rabies 
endemic areas. Travelers 
visiting foreign areas of 
endemic rabies for more 
than 30 days. 
 
Primary course. Serologic 
testing or booster 
vaccination every 2  
years 2 
 
Infrequent 
(greater than 
population at 
large) 
 
Exposure nearly 
always episodic with 
source recognized. 
Mucous membrane, 
bite, or non-bite 
exposure 
 
Veterinarians and animal 
control and wildlife 
workers in areas of low 
rabies endemnicity. 
veterinary students. 
 
Primary course; no 
serologic testing or 
booster vaccination. 
 
Rare 
(population at 
large) 
 
Exposures always 
episodic. Mucous 
membrane, or bite 
with source 
unrecognized. 
 
U.S. population at large, 
including persons in rabies 
endemic areas. 
No vaccination necessary. 
 
1 Judgment of relative risk and extra monitoring of vaccination status of laboratory workers is the 
responsibility of the laboratory supervisor. 
2 Minimum acceptable antibody level is complete virus neutralization at a 1:5 serum dilution by 
RFFIT. Booster dose should be administered if the titer falls below this level. 
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Table 4. Rabies pre-exposure prophylaxis schedule  
 
 
Type of 
Vaccination 
 
 
Route 
 
 
Regimen 
 
Primary 
 
IM 
 
HDCV, RVA* , PCEC, 1.0 ml (deltoid area), 
On days 0, 7, and 21 or 28 
 
Booster1 
 
IM 
 
HDCV, RVA*, PCEC, 1.0 ml (deltoid area), day 0 
only 
 
 
1 Administration of routine booster dose of vaccine depends on exposure risk category 
as noted in the table above. 
 
*Although this vaccine is licensed, it is currently unavailable. 
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Table 5. Regimen for Rabies Post-exposure Prophylaxis by vaccination Status  
Vaccination Status 
of exposed person 
 
Treatment Dosage / administration 
guidelines for all ages 
 
Day of 
regimen 
 
Local wound 
cleansing 
Tetanus toxoid 
booster, if 
needed 
  
Human Rabies 
Immune 
Globulin (HRIG) 
 
20 IU/kg body weight, given once 
IM. As much as possible of the 
HRIG should be infiltrated into and 
around the wound, and the 
remaining given IM at a site distant 
from the vaccine 
(frequently the gluteals). 
Day 0 
 
Never previously 
vaccinated 
 
Rabies Vaccine Five 1-ml doses, given IM. Rabies 
vaccine must be given in the deltoid 
area of adults and older children. 
The vaccine may be given in the 
anterolateral thigh of young children. 
Never give rabies vaccine in the 
gluteals. 
Days 0, 3, 
7, 14, 28 
 
Local wound 
cleansing 
Tetanus toxoid 
booster, if needed 
  Previously 
vaccinated 
(Those who have 
completed a preexposure 
or postexposure 
regimen of Human Diploid 
Cell Vaccine (HDCV) or 
Purified Chick Embryo Cell 
Vaccine (PCEC), or who 
have received another 
vaccine and had a 
documented rabies 
antibody titer of > 1:5 by 
the Rapid Fluorescent 
Focus Inhibition Test 
(RFFIT) 
 
Rabies Vaccine Two 1- ml doses, given IM. Rabies 
vaccine must be given in the deltoid 
area. Never give rabies vaccine in 
the gluteals. 
 
Days 0, 3 
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Passive immunization  
Rabies immune globulin, human (HRIG) 
HRIG is a gamma globulin prepared by cold ethanol fractionation 
from the plasma of hyperimmunized humans. There are fewer adverse 
reactions to HRIG than to equine antirabies serum. Serum sickness has 
not been reported with human RIG. HRIG is very expensive 80 and as such 
is not widely used in the third world countries that carry the highest risk 
rabid animal injuries. 
 
Antirabies serum, equine  
This is concentrated serum from horses’ hyperimmunized with 
rabies virus. It is economical in comparison with HRIG however it carries 
risk of severe anaphylactic reactions on administration 81. It has been used 
in countries where HRIG is not available.  
 
Passive immunization regimens 
Rabies immune globulin (RIG) should be given with every primary 
post-exposure treatment  76. It is essential for severe exposure to infection: 
bites on the head, neck or hands or multiple bites. The WHO recommends 
that a skin test must be performed prior to the administration of ERIG in 
order to detect potential IgE- mediated hypersensitivity to equine serum 
proteins. A positive skin test does not rule out the use of ERIG when there 
is no alternative but special precautions should be taken to minimize 
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reactivity. Serum sickness is also a potential adverse reaction to ERIG 
and has been reported to occur 7 to 10 days after injection in 
approximately 1 to 6% of patients. Passive immunization provides some 
protection for the 7 to 10 days before vaccine induced immunity appears. 
RIG apparently neutralizes virus in the wound and enhances the T 
lymphocyte response to rabies 82. The dose of 20 units / kg body weight of 
HRIG (or 40 units / kg equine RIG) should be infiltrated deep around the 
wound. If this is anatomically impossible, the rest may be given by i.m. 
injection at a site remote from the vaccine, but not into the gluteal region 83. 
For multiple bites the RIG can be diluted two- or three-fold in saline to 
ensure infiltration of all wounds. The recommended dose of RIG must not 
be exceeded as this will impair the immune response to the vaccine.   
 
Efficacy of post-exposure treatment 
Indian studies have shown that the untreated mortality from proven 
rabid dog bites is 35 to 57% 29. Optimal modern post-exposure treatment 
given on the day of the bite to healthy recipients is practically 100% 
effective. However recently John and Patnaik 6, reported development of 
rabies in an otherwise healthy 5 year old girl despite post-exposure 
prophylaxis with PCECV and HRIG. Similar isolated cases of development 
of rabies, despite  complete and prompt treatment with modern products, 
have been reported in animals 84 and human beings i.e from India 6, 
Pakistan 7, Thailand 4,5 and sub-Saharan Africa 85. These reports are 
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questioning the authenticity of cell culture rabies vaccines available in the 
community. One of the suggested causes for cell culture rabies vaccine 
failure is reduced potency of these vaccines due inadequate cold chain. 
Reports point towards the frequent power failures and the lack of 
refrigeration facilities in the community leading to loss of vaccine potency 7. 
Hence a pilot study to evaluate the potency of rabies vaccines available in 
the community, i.e out of the hospital / laboratory, offered for prophylactic 
use in human and veterinary establishments has been indicated 3.                                             
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Materials and methods 
 A cross sectional survey to assess the adequacy of cold chain for cell 
culture rabies vaccines during transportation and storage. 
 
In this cross sectional survey three districts of South India i.e.  
Vellore (Tamil Nadu), Kolar (Karnataka), and Chittoor (Andhra Pradesh) 
were chosen as study areas.  A questionnaire was prepared keeping in 
mind the cold chain requirements for vaccine transport and storage (see 
annexure 1). A total of 102 pharmacy shops situated in the study areas, 
Vellore and Ranipet [Vellore Dist], Kolar and Mulbagal [Kolar Dist], 
Chittoor and Bangaarupalyam [Chittoor Dist],   were contacted during the 
study. Of the 102 pharmacy shops contacted, 29 declined to participate 
and the rest seventy three pharmacy shops agreed to provide information 
on their vaccine storage system and allowed us to document the 
temperature in their vaccine storage compartments. A single observer 
visited the pharmacy shops and interviewed pharmacists using the earlier 
mentioned questionnaire. The type of refrigerator / freezer unit, 
temperature-monitoring equipment and records were noted, as were the 
locations of vaccines in refrigerator and freezer, and the presence of 
expired vaccines. Other information collected included the following: staff 
training, use of written guidelines, receipt of vaccine deliveries, different 
brands of cell culture rabies vaccines, number of vaccines being sold per 
month, average duration of rabies vaccine storage in the pharmacy and 
the professional educational level of the individuals designated as vaccine 
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handlers. At each pharmacy, interviewer measured the central core 
temperature of the vaccine refrigerator using standard fluid filled 
thermometer and noted the position of the vaccines in the refrigerator as 
well as the presence of other items. 
Collection of cell culture rabies vaccines (PCECV) from the community 
based pharmacies 
Based on the cross sectional survey, well maintained and poorly 
maintained pharmacies were identified. Eight PCECV vaccine vials were 
collected from eight poorly maintained pharmacies and eight PCECV 
vaccine vials were collected from eight well maintained pharmacies.  
Heat simulation studies 
Twenty vials of PCECV rabies vaccine from the same 
manufacturer’s batch were collected from Christian Medical College 
Hospital Pharmacy. Christian Medical College is a tertiary care teaching 
hospital in South India. To simulate the exposure to high temperatures 
during storage, ten vials were incubated at 37 0 C for 12 hours / day for 15 
days. At the end of every incubation period vials were transferred to 
recommended storage conditions (2 to 8°C). The other ten PCECV vials 
were stored at recommended storage conditions (2 to 8°C) throughout the 
study. 
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Estimation of glycoprotein content in PCECV samples 
Virus bound glycoprotein in the PCECV samples, collected from the 
community based pharmacies as well as vaccine vials used for heat 
simulation studies, was assessed using an enzyme linked immuno sorbent 
assay (ELISA) procedure described by  Fournier – Caruana  et al, 2003 
86. The monoclonal antibodies (mAb-D1), secondary antibodies, reference 
vaccine and experimental protocols were obtained from Institut Pasteur, 
Paris, France. 
In-vitro test for rabies vaccine potency testing 
Principle of the rabies glycoprotein enzyme immunoassay 
ELISA represents one of the in vitro tests which can be used for 
rabies vaccine potency testing 86. The principle of this test is based on the 
measurement of the glycoprotein content in rabies vaccine by ELISA 87 
after the immunocapture of rabies virus glycoprotein 88. The vaccine to be 
tested is incubated in a plate previously sensitized with anti-glycoprotein 
antibody (polyclonal or monoclonal antibody). Bound antigens are 
subsequently identified by adding the same antibody labelled with 
peroxidase which is revealed in the presence of substrate and chromogen. 
Comparison of absorbance measured for the tested vaccine with the 
absorbance of the reference vaccine permits the determination of the 
glycoprotein content. 
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Biological material 
Monoclonal antibody for coating 
Semi-purified Immunoglobulins (IgG) anti-rabies glycoprotein: 
purified from mouse ascitic fluid immunized with hybridome 01-25WI-
1805 (Collection Nationale de Culture de Microorganismes-Institut 
Pasteur Paris). Specificity: anti-rabies glycoprotein (PV strain) direct to 
antigenic site III. IgG 01 A: 530 µl was diluted 1 / 200 
Peroxidase conjugate 
  The same IgGs conjugated with peroxidase.  
           IgG 01 A-PO: 530 µl was diluted 1/ 200 
Antigen for validation 
Inactivated and purified rabies vaccine (PV strain). First 
dilution: 1/10 after hydration with 1 ml of distilled water. Antigen 
concentration after 1/10 dilution: 1000 ng / ml. 
Preparation of monoclonal antibodies 
 
In brief monoclonal antibodies were prepared as described by 
Lafon  89 after immunization of BALB/c mice with inactivated and purified 
rabies virus (Pasteur virus strain). MAb-D1 (IgG1 isotype) recognizes the 
antigenic site III (involved in virus neutralizing Ab induction) of native but 
not β-mercapto-ethanol and / or sodium dodecyl sulfate (SDS) - treated 
glycoprotein 90. It neutralizes lyssaviruses belonging to the genotype 1 
(rabies viruses: Pasteur virus (PV), challenge virus standard (CVS) and 
Pitman-Moore (PM) strains) and to the genotype 6 (European bat 
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lyssavirus 2 (EBL2)). Produced as ascitic fluid and diluted 1:106, it 
neutralizes 2 X 10 5 fluorescent focus units / ml of virus (PV strain), 
indicating that it possesses a very high virus neutralizing activity. Before 
its use in ELISA, the ascitic fluid was precipitated with ammonium sulfate 
(40% saturation) and centrifuged. The pellet was suspended in chilled 
distilled water and dialyzed against PBS. Concentrated immunoglobulins 
were sterilized by filtration and used to coat ELISA microplates and to 
prepare peroxidase conjugate as previously described 91.  
Buffers and reagents 
 
    Carbonate 0.05 M 
    NaCO 3, 10 H 2O. .................................................................. ...14. 30 g 
 Distilled water.......................................................... to make 1000.00 m1 
Bicarbonate 0.05M: 
    NaHCO 3 ........................................................................................4.20 g 
 Distilled water.......................................................... to make 1000.00 m1 
Carbonate buffer 0.05 M   pH=9.6: 
 Bicarbonate 0.05 M.................................................................... 900.00 ml 
Adjusted pH=9.6 with carbonate 0.05 M 
Phosphate buffered saline  pH=7 concentrated 10 times (PBS l0X): 
 NaCl.............................. 80.00 g         KCl ....................................2 .00 g 
 Na2PO4, 12 H2 0 11.33g         KH2PO4……………………..2.OO g 
 Distilled water…………………………………………to make 1 000.00 ml 
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PBS-Tween   pH=7: 
 PBS 10 X ...................................... 100.0 m1 
 Tween 20 ............................................0.5 m1 
 Distilled water.............. to make 1000.0 ml 
PBS-Tween-BSA   pH=7: 
 PBS l0 X...................................................................................... 10 .00 ml 
        Tween 20. .................................................................................... 0.05 ml 
    Bovine serum albumin (Fraction V)...........................................0.50 g 
 Distilled water............................................................to make 100.00 ml 
Adjusted pH= 7 with 4N NaOH 
Buffer for peroxidase substrate   pH=5.6 (citrate buffer): 
    Tri-sodium citrate, 2H2O (Na3C6H5O7, 2H2O)................................... 11.67 g 
    Citric acid, 1 H2O ........................................................................... 2.l 7 g 
 Hydrogen peroxide 30% (110 vol)............................................ 1.00 m1 
 Distilled water........................................................... to make1000.00 m1 
Substrate-Chromogen solution: 
 Ortho - phenylene diamine......................... 50 mg 
 Citrate buffer .......................................... 25 ml 
Stopping solution: 4N sulfuric acid 
Dilution id carried out in an ice bath 
 Cooled distilled water...................... 80.00 m1 
 H2SO4, 36N.........................................10.00 ml 
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Safety measures 
The washings were carefully carried out with an automatic 
apparatus (Fig 2b) and drying plate after inverting it on an absorbent 
paper after each washing. All reagents were adjusted to the laboratory 
temperature by waiting 10 min before use. Vaccines or infected cell 
supernatants to be tested are often inactivated nevertheless, samples 
were considered infectious and health and safety precautions were 
observed. Before working, the plan for distribution and identification of 
samples was established. Reference antigen or vaccine and samples 
were diluted in tubes and not in the sensitized plate. 
 
Microplate sensitization 
Microplate was sensitized with purified anti-glycoprotein 
monoclonal antibodies by adding in each well 200 µl of appropriate 
dilution of antibodies. [ Different dilutions of antibody were previously 
tested to determine the optimal concentration. About 1 µg / well is 
generally required ]. For sensitization, antibodies were diluted in 
carbonate buffer pH=9.6. After an incubation for 3 hour at 370 C in a 
humidified atmosphere (or covered with a sealer sheet) (Fig 2a), well 
content was aspirated and plate was inverted and dried on absorbent 
paper at laboratory temperature for 5 mn. Each well was then filled 
with 300 µl of 0.3% bovine serum albumin and 5% sucrose dissolved in 
carbonate buffer. After incubation at 370 C for 30 min, well content was 
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aspirated. The plate was inverted, dried for 1 min on absorbent paper at 
laboratory temperature and was immediately used or stored sealed at -
200 C until use. 
The assay 
The sensitized plate was washed 5 times in PBS- Tween, inverted 
and dried for 1 min on absorbent paper. The first well (IA) (or all wells of 
the line 1) received 200 µl of PBS -Tween-BSA and served as blank 
control. Two hundred microliters of 5, two folds serial dilutions (in PBS –
Tween -BSA) of the reference vaccine were distributed in duplicate in 
wells of the lines 2 and 3. The first dilution contains about 1 µg / ml of 
rabies glycoprotein. Two hundred µl of vaccines samples (serially two 
folds diluted in PBS-Tween-BSA) were distributed in duplicate in each 
well. The plate was covered with a sealer sheet and incubated for 1 hour 
at 370 C. Then, well content was aspirated and plate was washed 5 
times with PBS - Tween. Two hundred µl of an appropriated dilution (in 
PBS –Tween -BSA) of peroxidase-labelled antibodies was distributed in 
all wells. After incubation for 1 hour at 370 C, labelled antibodies were 
aspirated and plate was washed 6 times with PBS -Tween, inverted and 
dried for 1 min on absorbent paper. Then, all wells received 200 µl of 
substrate -chromogen solution. Plate was sealed and incubated in dark 
at room temperature for 30 mn. A yellow-orange color was developed 
and the reaction was stopped by adding in each well 50 µl of stopping 
solution (Fig 2d). 
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Interpretation 
 
The bottom of the plate was carefully wiped with absorbent paper. 
The optical density (OD) of each well was measured at 492 nm with an 
ELISA plate reader (Fig 2c). For the evaluation of glycoprotein content a 
reference vaccine was used. The reference vaccine contains purified viral 
particles with a well known glycoprotein content (µg / ml) directly 
determined (for example, determination of total viral protein and 
percentage of glycoprotein by SDS - polyacrylamide gel electrophoresis) 
or indirectly determined in ELISA using a calibrated vaccine. Standard 
curve was generated using spline parameter. The KC 4 software ( version 
# 2.7,Rev # 8, Bio -Tek Instruments) was used to express the OD values 
as glycoprotein content in ng / ml, as previously used by other workers 92. 
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Sample size determination and statistical analysis 
Sample size calculations of PCECV vials for the ELISA suggested 
large, unfeasible numbers. Hence, we chose the above stated numbers of 
PCECV vials and planned to do retrospective power analysis to determine 
whether our study suggests equivalence between the groups. Statistical 
analysis later suggested that it is not possible to show significant 
differences even with large sample sizes. The non-parametric test, Mann -
Whitney U Test, was used for statistical comparison of the glycoprotein 
contents of the vaccines. 
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Fig 2.  
 
 
 
 
 
2a. ELISA plate incubator                          2b. Automated ELISA plate washer                          
 
 
 
 
2c. ELISA plate reader                             2d. ELISA plate loaded with PCECV samples 
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Results 
We contacted 102 pharmacies during the study, of which 73 
pharmacies agreed to participate in the study. All these pharmacies were 
storing the PCECV “Rabipur”, while only 12 (16.4%) of these 73 
pharmacies were storing the PVRV “Verorab”. Other brands of rabies 
vaccines like PDEV (Vaxirab), PVRV (Abhyarab) and HDCV (Rabivax) 
were not available in any of these pharmacies. “Rabipur” was the most 
commonly prescribed rabies vaccine followed by “Verorab”. None of these 
pharmacies were storing either equine antirabies serum or human rabies 
immunoglobulins. Pharmacies were obtaining these vaccines from 
Chennai (Vellore & Ranipet), Bangalore (Kolar & Mulbagal) and Thirupathi 
(Chittoor & Bangarupalaym). Average number of rabies vaccines sold / 
pharmacy / month was 3 - 5 in urban areas i.e Vellore, Kolar and Chittoor 
while the same was about 1-2 in semi urban areas i.e , Ranipet, Mulbagal 
and Bangarupalyam. The maximum duration of “in pharmacy storage” for 
a vaccine vial was about 6 months in all the pharmacies. Even though 
three different state electricity boards were supplying the electricity to 
these pharmacies, the pattern and duration of power outage was almost 
similar in all the pharmacies. Other results of the survey are given in Table 
6. Our results show that rabies vaccines are exposed to non-ideal 
temperatures during transport and storage. 
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To assess the effect of poor cold chain on the potency of rabies 
vaccines we collected PCECV vials from poorly maintained (n=8) and well 
maintained pharmacies (n=8). We evaluated the potency of these 
vaccines indirectly by measuring the virus bound glycoprotein content in 
these vaccine samples. Our results (Tables 7, 8, 11, 12 & 15) show that 
there is no significant difference in the glycoprotein content of the vaccines 
collected from either poorly maintained and well maintained pharmacies. 
The next experiment was conducted to evaluate the effect of high 
temperatures on the rabies vaccine potency. The rabies vaccines in the 
community are exposed to temperatures around 33 to 370C (usual 
temperature in these parts of South India) for a maximum about 180 hrs 
(average 1hour / day for of six months). Hence we simulated this condition 
in our laboratory by incubating the vaccines (n=10) at 370C for 180 hrs. 
Similar number (n=10) of vaccines from the same manufacturer’s batch, 
stored at recommended temperature (2 to 80 C), were used as controls. 
Glycoprotein content was measured in all these vaccines as an indirect 
measure for vaccine potency. Our results (Tables 9,10,13,14 & 16) show 
that there is no significant difference in the glycoprotein content of these 
two groups of vaccines. 
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Table 6. Rabies vaccine storage practices in South India 
 
 
Attribute 
 
Total 
 
Percentage 
 
Number of Personnel Handling the Vaccines 
1. Trained 
2. Untrained 
 
289 
108 
181 
 
 
37.4 
62.6 
 
Power Cuts ( Duration / Day ) 
1. 30 min – 1 hour 
2. 1hr – 2 hrs 
 
 
51 
22 
 
 
69.9 
30.1 
 
Alternate Power Facilities 
1. Available 
2. Unavailable 
 
 
11 
62 
 
 
15 
85 
 
Condition of the Refrigerator 
1. Satisfactory 
2. Not satisfactory 
 
 
27 
46 
 
 
37 
63 
 
Thermometer in the Vaccine Compartment 
1. Present 
2. Absent 
 
 
Nil 
73 
 
 
0 
100 
 
Recording of Vaccine Compartment Temperature 
1. Once daily 
2. Once weekly 
3. Once monthly 
4. Occasionally 
5. Never 
 
 
Nil 
Nil 
Nil 
5 
68 
 
 
0 
0 
0 
6.8 
93.2 
 
Refrigerator Use  
1. Switched off at night 
2. Used round the clock 
 
 
12 
61 
 
 
16.4 
83.6 
 
Temperatures Documented During Interview* 
1. Within ideal range ( 2 - 8○ C ) 
2. Not within the ideal range 
*  minimum recorded temperature : 6○ C 
   maximum recorded temperature : 32○ C 
 
 
 
14 
59 
 
 
 
19.2 
80.8 
 
Maintenance of Cold Chain During Transport 
1. Adequate 
2. Inadequate 
 
 
48 
25 
 
 
65.8 
34.2 
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Table 7. Vaccines from poorly maintained pharmacy shops - Mean OD values 
 
 
 
 1/10 1/20 1/40 1/80 1/160 
Std 1.782 1.2875 0.8010 0.3895 0.1665 
1 0.5120 0.3075 0.1660 0.0800 0.0350 
2 0.5075 0.2815 0.1280 0.0525 0.0190 
3 0.4695 0.2645 0.0940 0.0320 0.0170 
4 0.4375 0.2085 0.0760 0.0300 0.0150 
5 0.5390 0.3190 0.1715 0.0840 0.0375 
6 0.4715 0.2595 0.0855 0.0345 0.0190 
7 0.4580 0.2690 0.1385 0.0640 0.0300 
8 0.4625 0.2250 0.0825 0.0270 0.0295 
 
 
 
Table 8. Vaccines from well maintained pharmacy shops – Mean  OD values 
 
 
 
 
 1/10 1/20 1/40 1/80 1/160 
Std 1.3925 1.1965 0.6675 0.2930 0.1825 
1 0.4570 0.2515 0.1400 0.0725 0.0250 
2 0.4065 0.2315 0.0900 0.0435 0.0235 
3 0.4030 0.2123 0.0890 0.0365 0.0245 
4 0.3810 0.2375 0.0820 0.0365 0.0150 
5 0.4385 0.2495 0.1295 0.0625 0.0330 
6 0.4480 0.2390 0.0900 0.0565 0.0235 
7 0.4395 0.2505 0.1225 0.0520 0.0265 
Std 1.0495 XXX 0.3930 0.2775 0.1440 
8 0.1715 0.1530 0.0425 0.0190 0.0130 
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Table 9.  Non-heated vaccines - Mean OD values 
 
 
 
 
 
 
Table 10. Heated Vaccines – Mean OD values 
 
 
 
 1/10 1/20 1/40 1/80 1/160 
Std 0.8715 0.5940 0.4180 0.2280 0.0995 
1 0.3800 0.1915 0.1010 0.0380 0.0205 
2 0.3185 0.1455 0.0670 0.0310 0.0121 
3 0.2266 0.1340 0.0520 0.0250 0.0110 
4 0.2630 0.1340 0.0580 0.0150 0.0130 
5 0.3115 0.1715 0.0900 0.0390 0.0185 
6 0.2280 0.1130 0.0610 0.0280 0.0140 
7 0.3030 0.1545 0.0750 0.0285 0.0130 
8 0.2790 0.1310 0.0550 0.0225 0.0135 
Std 1.0495 XXX 0.3930 0.2775 0.1640 
9 0.2885 0.1605 0.0715 0.0330 0.0170 
10 0.2920 0.1575 0.0805 0.0260 0.0175 
 
 
 
 
 
 1/10 1/20 1/40 1/80 1/160 
Std 1.481 1.126 0.8695 0.284 0.210 
1 0.4065 0.1770 0.0785 0.0155  
2 0.3560 0.1455 0.0680   
3 0.2440 0.1455 0.0815   
4 0.2305 0.0880 0.0415   
5 0.4075 0.2090 0.0910 0.0155  
6 0.3120 0.1105 0.0680   
7 0.3790 0.2450 0.0810 0.0150  
Std 1.0495 XXX 0.3930 0.2775 0.1180 
8 0.2565 0.1520 0.0785 0.0205 0.0165 
9 0.2850 0.1600 0.0795 0.0220 0.0190 
10 0.2635 0.1375 0.0685 0.0225 0.0120 
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Table 11. Vaccines from poorly maintained pharmacy shops – Mean concentrations 
 
 
 
 1/10 1/20 1/40 1/80 1/160 
Std 982.225 510.28 239.735 134.84 59.5195 
1 174.54 107.855 59.348 23.574  
2 160.575 93.6285 30.1565   
3 150.16 74.1395 21.4095   
4 184.525 111.62 61.3675   
5 161.23 91.85 26.216   
6 173.06 99.449 44.436   
7 155.315 95.13 48.9195 14.848  
8 158.29 79.39799 24.799   
 
 
 
Table 12. Vaccines from well maintained pharmacy shops – Mean concentrations  
 
 
 
 
 1/10 1/20 1/40 1/80 1/160 
Std 967.845 498.48 252.575 118.98 73.078 
1 177.96 102.87 50.8525   
2 160.335 94.69 25.512   
3 159.025 86.2725 25.512   
4 151.22 97.082    
5 171.495 102.065 44.502   
6 184.815 97.7975    
7 171.845 102.465 39.7345   
Std 998.945 XXX 239.15 143.2275 57.704 
8 62.726 50.6665    
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Table 13. Non-heated vaccines - Mean concentrations 
 
 
 
 1/10 1/20 1/40 1/80 1/160 
Std 903.75 500.025 250.005 124.835 62.844 
1 170.17 76.493 44.7860   
2 153.10 65.7465 41.9375   
3 106.91 66.47 45.608   
4 100.416 47.4195 34.828   
5 170.4 90.2695 45.465   
6 133.135 53.8635 41.953   
7 171.09 112.078 45.4715   
Std 998.945 XXX 239.15 143.2275 57.704 
8 123.855 47.8395    
9 146.365 55.117    
10 129.315 41.1745    
 
 
 
Table 14. Heated Vaccines – Mean concentrations  
 
 
 
 1/10 1/20 1/40 1/80 1/160 
Std 986.165 476.04 270.955 123.275 55.216 
1 236.21 101.69 55.916 30.5755 24.523 
2 185.57 76.8775 41.52 28.075 20.5975 
3 133.765 71.346 35.7135 26.0115 20.132 
4 145.815 64.268 38.004 22.6855 21.075 
5 180.32 90.409 51.0355 30.927 23.8325 
6 123.11 61.235 39.159 27.039 21.5525 
7 175.72 81.479 44.7515 27.2125 22.0335 
8 156.76 69.785 36.842 21.792 20.7545 
Std 998.945 XXX 239.15 143.2275 57.704 
9 149.265 55.4705    
10 151.03 53.515    
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Table 15. Glycoprotein content of PCECV 
 
 
 
a: compared to vials from poorly –maintained pharmacies 
 
Abbreviations:  n: number of vials; SEM: Standard error of mean  
 
Numbers in square brackets give the 95% confidence interval. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean glycoprotein content in ng / ml (SEM) according to dilution 
used 
 
 
 
PCECV studied 
( n )   
1/10                 p value 1/20                 p value 1/40               p value
 
Obtained from 
poorly maintained 
pharmacies  
( 8 ) 
 
 
164.7 (4.1) 
 
[ 155.1 , 174.3 ] 
 
94.1 (4.5) 
 
[ 83.4 , 104.8] 
 
39.6 (5.7) 
 
[ 26.2 , 53.0] 
 
Obtained from well 
maintained 
pharmacies  
( 8 ) 
 
 
154.9 (13.8)  
 
[ 122.5 , 187.4 ] 
 
                             1.0 a  
 
 
91.7 (6.2)     
 
[ 77.1 , 106.3 ] 
 
                           0.83 a 
 
37.2 (4.0)      
 
[ 23.1 , 51.4 ] 
 
                         0.88 a
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Table 16. Glycoprotein content of PCECV 
 
 
 
a: Compared to heated vials 
 
Abbreviations:  n: number of vials; SEM: Standard error of mean  
 
Numbers in square brackets give the 95% confidence interval. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean glycoprotein content in ng / ml (SEM) according to dilution 
used 
 
 
 
PCECV studied 
( n )   
1/10                 p value 1/20                 p value 1/40               p value
 
Heated (10)  
 
 
 
 
163.8 (10.3) 
 
[ 140.6 , 186.9 ] 
 
72.6 (4.9) 
 
[ 61.6 , 83.6 ] 
 
42.9 (2.3) 
 
[ 39.3 , 46.5 ] 
 
 
Non – heated  (10 )    
 
    
 
140.5 (8.2)      
 
[ 121.9 ,  159.1 ] 
 
                           0.11 a 
  
 
65.7 (7.0)     
 
[ 49.9 , 81.4 ] 
 
                           0.23 a 
 
42.9 (1.2)      
 
[ 36.8 , 48.9 ] 
 
                         0.48 a
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Discussion  
In India a large number of people exposed to bites from potentially 
rabid animals do not receive cell culture rabies vaccines due to financial 
constraints and therefore still receive reactogenic nerve tissue vaccine. To 
resolve this problem, the World Health Organization (WHO) recommended 
the discontinuation of the production and usage of NTV in 1992 and 
national authorities have demonstrated a commitment to phase out its use 
in favor of cell culture vaccines 67.  Epidemiological data collected from 
field studies conducted by the National Institute of Communicable 
Diseases in Delhi indicate that approximately 2.12 million animal bites 
occur annually. Of these, 1.1 million patients elect to receive post 
exposure treatment, 0.45 million of which receive NTV which is given free 
of charge in the public sector and 0.65 million patients receive cell culture 
vaccines on a self-financing basis 2. The main limiting factors for replacing 
NTV with cell culture vaccines are the limited availability and high cost of 
cell culture vaccines. Our results show that cell culture vaccines like 
PCECV and PVRV are available in urban as well as semiurban areas and 
are being used in rabies prophylaxis regularly.  Since isolated reports of 
rabies vaccine failure are questioning the effectiveness of cell culture 
rabies vaccines, our study, which evaluates the effect of inadequate cold 
chain on the potency of PCECV samples, becomes very important not 
only for the health professionals but also for policy makers with respect to 
their efforts in rabies prevention. 
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We conducted a community based study of vaccine storage and 
handling in pharmacies situated in South India. We selected three 
adjoining districts from three states in South India. In each district, a taluk 
head quarters and a district head quarters were chosen for the study, to 
represent both semi urban and urban systems respectively. Our intention 
was to generalize the results to these three South Indian states and offer a 
baseline against which to compare improvements in quality assurance 
practices. Key risk factors for proper vaccine storage found in pharmacies 
were the use of old and defective refrigerators to store vaccines, lack of 
trained personnel, frequent power outage, lack of alternate power 
facilities, failure to place thermometer in the refrigerator, and failure to 
monitor temperatures in all vaccine storage compartments.  
The findings from our study are consistent with those from other 
studies that found problems with vaccine storage and handling 16,19,20, 23,24. 
In particular, most of the staff responsible for vaccine storage had poor 
knowledge about maintaining the cold chain and were unaware of 
recommendations on vaccine storage. Storage of food or laboratory 
specimens in vaccine refrigerators meant that refrigerators were opened 
frequently and that both the code of practice for storing vaccines and the 
food hygiene regulations were broken. Moreover, the findings emphasize 
the need for daily temperature monitoring in all refrigerators. This is 
especially critical when refrigerators are older and can no longer maintain 
temperatures of 2 to 8 o C. The other interesting observation in our study 
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was that 16.4 % of the pharmacies accepted that they switch off their 
refrigerators during the night time. In reality this number could be still high, 
which might further jeopardize the cold chain system.  
 
Even though we included only the pharmacies storing rabies 
vaccines for our study, these pharmacies were storing other vaccines as 
well. Our study indicates that in addition to rabies prophylaxis, other 
immunization programmes are under the risk of failure due to inadequate 
cold chain. This lack of attention to correct vaccine storage contrasts 
sharply with common practices in developing countries, where meticulous 
attention is paid to vaccine storage 93.  Hence to achieve success in any 
vaccination programmes, particularly in rural and less populated urban 
areas, need of the hour is to bring the vaccine storage and transportation 
policies in line with the current guidelines 13. This can be achieved through 
educating the vaccine handlers about the importance and maintenance of 
cold chain, and strict observation of guidelines from the licensing 
authorities.   
 
Our study results show that cell culture rabies vaccines are indeed 
exposed to non-ideal temperatures. Rehan et al 7 while reporting two 
cases of rabies vaccine failure, observe that the efficacy of rabies 
vaccination may be high when administered under ideal conditions but its 
failure rate is considerable in their set up due to many reasons like 
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repeated power failures and lack of refrigeration facilities in the rural areas 
leading to reduced efficacy of vaccine, and the tendency of the patients or 
their attendants to take the vaccines to their homes and store and 
administer them in an unsupervised manner. Similar scenario exists in our 
community and it could be the explanation for rabies vaccine failure. 
However reduced vaccine potency may not be the only cause for 
vaccination failure as passive immunization with antirabies 
immunoglobulin is neither advised nor offered by most of the primary 
healthcare staff. Furthermore, Hemachudha and colleagues 94, while 
reporting rabies vaccine failure cases from Thailand, mentioned that, 
rabies vaccine failures may be due to causes other than reduced vaccine 
potency. However to exclude the possibility of reduced vaccine potency 
due to inadequate cold chain, a pilot study to assay the potency of rabies 
vaccines and immune globulins being offered for prophylactic or 
therapeutic usage in human and veterinary establishments in the affected 
community is indicated 3. That would vindicate the authenticity of the two 
integral components of the therapy against rabies prescribed at various 
rabies immunization centres. 
 
This proposal has been followed up, in part, in our study by 
indirectly measuring the potency of PCECV samples collected from the 
community based pharmacies. Our results showed that potency of the 
vaccines obtained from the poorly maintained pharmacies was similar to 
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the vaccines from well maintained pharmacies. Our next set of 
experiments which aimed at assessing the effect of high storage 
temperatures on PCECV potency, by simulating those conditions in the 
laboratory, showed that potency of the PCECV remains intact even after 
storing these vaccines at non-ideal temperature [370C] for 180 hours. 
These results support the earlier reports depicting the thermostability of 
PCECV 94. Our study shows that reduced vaccine potency, due to high 
storage temperatures and / or inadequate cold chain maintenance during 
storage and transportation, may not be the cause for rabies vaccine 
failures seen in developing countries.  
 
Failures of treatment are failure to deliver the three components of 
post exposure management i.e. wound wash with soap and water, correct 
and prompt active and passive immunization, or failure of the patient to 
mount an immune response. For example: if there is delay in starting 
treatment; failure to complete the course; injections of vaccine or RIG into 
the gluteals; or immunosuppresion by drugs, HIV, cirrhosis, concurrent 
treatment with chloroquine or other illness. The other clinical picture that 
presents as post-exposure prophylaxis failure is development of disease 
due to a short incubation period. If the animal bites in an area with sparse 
nerve endings (e.g., the leg), there is a window period of up to a few days 
between the bite and virus entry into nerve endings. In such cases active 
immunization alone may suffice. In the recommended vaccination 
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schedule, antibody production would commence after the second dose, 
and will be detectable by laboratory testing before day 10. However, if the 
biting animal was rabid, passive immunization must be given irrespective 
of the site of bite. The incubation period is too short in case of bites on 
areas with high density of nerve endings e.g., face, hand, genitalia. Here, 
viruses may come directly into contact with nerve endings. In these cases 
in addition to the wound wash and active immunization, passive 
immunization is mandatory. While soap disrupts rabies virus particles 
instantaneously by dissolving the lipid coat, rendering them non-infectious, 
water disperses soap into the wound and also mechanically removes 
unadsorbed virus particles. If first aid was delayed or unsuccessful, then 
virus enters and multiplies in the cells, and huge numbers are released 
into the surrounding tissue. Eventually viruses meet with nerve endings 
and enter nerve cells. Since each cell cycle of multiplication takes several 
hours, passive immunization with equine RIG / HRIG prevents the virus 
entry into fibroblasts, either in the first cycle itself or in subsequent cycles. 
Thus, virus entry into nerve endings is prevented, especially by the locally 
injected immunoglobulin 95. Even though in some cases of rabies vaccine 
failures passive immunization is given, the details regarding time delay in 
initiating the wound treatment and initiation of passive immunization is not 
given. Our study also shows that equine RIG or HRIG is not available in 
any of the inspected pharmacies indicating that even though active 
immunization is given promptly passive immunization is not given. The 
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reasons for this could be high cost and lack of availability of equine RIG or 
HRIG 96. Thus the reported cases of rabies vaccine failure are not due to 
‘therapeutic failure’ of ‘appropriate’ post-exposure prophylaxis, but due to 
inadequate post exposure prophylaxis. Hence it seems possible that this 
surreal cell culture rabies vaccine failure is due to delay in initiating wound 
treatment and inadequate passive immunization and not due to reduced 
potency of these vaccines. We suggest a community based survey to 
study the post exposure rabies prophylaxis practices to give more 
evidence in this regard. 
 
The major limitation with our cross sectional survey is small sample 
size. Although our study is small, it highlights serious problems with 
vaccine transportation and storage that could jeopardize the success of an 
immunization programme. Our inability to use NIH test, due to lack of 
necessary biosafety infrastructure, to evaluate the rabies vaccine potency 
is the other major concern. Even though NIH test is the standard test for 
assessing rabies vaccine potency its shortcomings are well known. Hence 
we used immunocapture ELISA test as an indirect measure for rabies 
vaccine potency. Immunocapture capture ELISA is reliable and correlates 
well with the NIH test  86. Small number of PCECV were tested for practical 
reasons. Sample size calculations of PCECV vials for the ELISA 
suggested large, unfeasible numbers. Hence, we chose the above stated 
numbers of PCECV vials and planned to do retrospective power analysis 
to determine whether our study suggests equivalence between the groups. 
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Statistical analysis later suggested that it is not possible to show 
significant differences even with large sample sizes. 
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Conclusions 
 
Our findings show that the cold chain maintenance during transport 
and storage of PCECV, a commonly used cell culture rabies vaccine in 
South India, is inadequate and these vaccines are indeed exposed high 
temperatures. However there was no significant difference in the 
glycoprotein content, an indirect measure of vaccine potency, of the 
PCECV samples collected from poorly maintained pharmacies and well 
maintained pharmacies. Similar results were seen in the heat simulation 
study wherein the glycoprotein content of PCECV samples exposed to 
high temperature was similar to PCECV samples maintained at 
recommended temperatures. Our study indicates that PCECV vaccines 
are thermostable and that they retain their potency despite inadequate 
cold chain. We conclude that reduced vaccine potency due to inadequate 
cold chain may not be the cause for the failure of post exposure rabies 
prophylaxis. Delay in initiating the wound treatment, inadequate passive 
immunization, immunodepression, chronic disease, surgery under 
anaesthesia, concurrent use of alcohol or drugs, and antagonism of 
vaccine effects by immunoglobulins could be the reasons behind this 
surreal cell culture rabies vaccine failure.  
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Annexure 1. 
 
VACCINE STORAGE PRACTICES IN SOUTH INDIA        sl no: 
 
1. NUMBER OF PERSONNEL RESPONSIBLE FOR HANDLING VACCINES  
    AND  THEIR EDUCATIONAL STATUS. 
    A.                                                                     B. 
     
C. D. 
                                                                                   
2. REFRIGERATOR. 
  A. used / not used.                                                     B. make - <5 yrs / >5 yrs 
    
C. condition-satisfactory / unsatisfactory                   D. store other items – yes /  
              no 
 
   E. used round the clock / switched off during some time of the day. (          ) 
 
   F. max-min thermometer use - yes / no 
 
3. POWER SOURCE (                                                                   ) 
  A. alternate power source - available /not available. 
 
  B. power cut -                / day,                  / week. 
 
4. TEMPARATURE MEASUREMENT IN REFRIGERATORS. 
    A. monitoring-twice daily / once daily / weekly / monthly 
 
    B. usual temperature range - 
 
 C. temperature recorded during the interview- 
 
5. VACCINES THEY MARKET. 
                     Storage Conditions                        Storage Conditions                            
  
    A.                                                                         D. 
    B.                                                                         E. 
    C.                                                                         F. 
6. RABIES VACCINE. 
  A. brands available- 
 
  B. manufacturing date- 
 
  C. sales-                  / week,                        / month 
 
D. source and transport- 
